CA
BBIO icon

Continuum Advisory’s BridgeBio Pharma BBIO Stock Holding History

Continuum Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34
Closed -$977 – 1709
2024
Q1 		$977 Buy
+34
New +$1.16K ﹤0.01% 1471

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Continuum Advisory's BBIO Position: Q2 2024 in Review

Continuum Advisory sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 34 shares — an estimated $977 sold.

Continuum Advisory first reported a position in BBIO in Q1 2024 and held it in 1 quarter. The position peaked at $977 in Q1 2024. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • Continuum Advisory reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • Continuum Advisory sold 34 BridgeBio Pharma shares in Q2 2024, an estimated $977.
  • Continuum Advisory first reported a position in BridgeBio Pharma in Q1 2024 and held it in 1 quarter.
  • Continuum Advisory's BridgeBio Pharma position peaked at $977 in Q1 2024.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Continuum Advisory's 13F filing for Q2 2024, filed 19 Jul 2024.